China smartphone shipments slumped in June on inventory overhang: Jefferies
ST. PAUL, Minn. - Solventum (NYSE: SOLV), a leader in dental composites and restorative dentistry with a market capitalization of $12.8 billion and annual revenue of $8.25 billion, has announced a strategic partnership with SprintRay, a pioneer in chairside 3D dental printing technology. This alliance is set to develop and market durable, permanent same-day dental restorations, such as crowns, inlays, and onlays, which are traditionally created over multiple visits to the dentist. According to InvestingPro data, Solventum maintains a strong gross profit margin of 56%, demonstrating its operational efficiency in the dental materials market.
The collaboration aims to combine Solventum’s expertise in material science with SprintRay’s advanced 3D printing capabilities. The goal is to enhance the efficiency of dental procedures, reduce the time patients spend in the chair, and lower treatment costs. The initiative is expected to improve patient experiences and outcomes by providing in-office production of restorations. InvestingPro analysis reveals that Solventum has been profitable over the last twelve months, with EBITDA reaching $1.65 billion, suggesting strong financial backing for its innovative initiatives.
Karim Mansour, President of Dental Solutions at Solventum, expressed confidence that the partnership would transform dental care by streamlining the creation of long-lasting restorations in a single dental visit. Amir Mansouri, CEO of SprintRay, echoed this sentiment, highlighting the potential for significant advancements in restorative dentistry and the delivery of cost-effective treatments globally.
This partnership aligns with Solventum’s commitment to growth and digital innovation, following their recognition with seven Dental Advisor awards in 2024 and the introduction of four new products, including the first 3D printed aligner attachments and a new water-based fluoride treatment. With the stock currently trading at $74.93 and analyst targets ranging from $71 to $88, investors seeking deeper insights can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US equities and provide actionable intelligence for smarter investment decisions.
The details of this partnership will be further discussed at the International Dental Show (IDS) 2025 on March 26 in Cologne, Germany. Solventum’s historical focus on quality material science and recent strategic moves underscore its dedication to leading in the digital dentistry market.
This news release contains forward-looking statements regarding Solventum’s future performance and product offerings, which are subject to risks and uncertainties. These include global economic conditions, operational execution risks, and the highly regulated healthcare environment, among others.
The information in this article is based on a press release statement from Solventum.
In other recent news, Solventum reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $1.41, which fell short of the forecasted $1.50. Revenue for the quarter stood at $2.1 billion, marking a 2.3% organic growth. Piper Sandler analysts noted that despite these results, Solventum’s earnings per share and revenue exceeded consensus estimates, prompting them to raise the company’s price target to $84 while maintaining a Neutral rating. Solventum’s management issued guidance for 2025, forecasting organic growth of 1% to 2% and an EPS range of $5.45 to $5.65.
Additionally, the company has been undergoing a strategic transformation, focusing on divesting its Purification & Filtration division to enhance financial flexibility. Mizuho Securities adjusted its financial outlook for Solventum, raising the price target to $85 but maintaining a Neutral stance, reflecting cautious optimism about the company’s performance. Solventum’s Investor Day highlighted ambitious targets for 2028, including 4%-5% organic sales growth and a 10% EPS compound annual growth rate. Stifel analysts reiterated their Buy rating and $88 price target, expressing confidence in Solventum’s long-term objectives. These developments underscore Solventum’s strategic focus and ongoing efforts to improve its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.